Unknown

Dataset Information

0

Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks.


ABSTRACT: Oncolytic adenoviruses can trigger lysis of tumor cells, induce an antitumor immune response, bypass classical chemotherapeutic resistance strategies of tumors, and provide opportunities for combination strategies. A major challenge is the development of scalable production methods for viral seed stocks and sufficient quantities of clinical grade viruses. Because of promising clinical signals in a compassionate use program (Advanced Therapy Access Program) which supported further development, we chose the oncolytic adenovirus ONCOS-401 as a testbed for a new approach to scale up. We found that the best viral production conditions in both T-175 flasks and HYPERFlasks included A549 cells grown to 220,000 cells/cm² (80% confluency), with ONCOS-401 infection at 30 multiplicity of infection (MOI), and an incubation period of 66 h. The Lysis A harvesting method with benzonase provided the highest viral yield from both T-175 and HYPERFlasks (10,887 ± 100 and 14,559 ± 802 infectious viral particles/cell, respectively). T-175 flasks and HYPERFlasks produced up to 2.1 × 10? ± 0.2 and 1.75 × 10? ± 0.08 infectious particles of ONCOS-401 per cm² of surface area, respectively. Our findings suggest a suitable stepwise process that can be applied to optimizing the initial production of other oncolytic viruses.

SUBMITTER: Kuryk L 

PROVIDER: S-EPMC6387112 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks.

Kuryk Lukasz L   Møller Anne-Sophie W AW   Vuolanto Antti A   Pesonen Sari S   Garofalo Mariangela M   Cerullo Vincenzo V   Jaderberg Magnus M  

International journal of molecular sciences 20190131 3


Oncolytic adenoviruses can trigger lysis of tumor cells, induce an antitumor immune response, bypass classical chemotherapeutic resistance strategies of tumors, and provide opportunities for combination strategies. A major challenge is the development of scalable production methods for viral seed stocks and sufficient quantities of clinical grade viruses. Because of promising clinical signals in a compassionate use program (Advanced Therapy Access Program) which supported further development, we  ...[more]

Similar Datasets

| S-EPMC6343802 | biostudies-literature
| S-EPMC5136493 | biostudies-literature
| S-EPMC5552138 | biostudies-literature
| S-EPMC8508870 | biostudies-literature
| S-EPMC7697649 | biostudies-literature
| S-EPMC3272483 | biostudies-literature
| S-EPMC6562107 | biostudies-literature
| S-EPMC8334181 | biostudies-literature
| S-EPMC6025169 | biostudies-literature
| S-EPMC15501 | biostudies-literature